| --- | --- | --- | --- | |-------|----------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | Early Intervention with | | | | | Mission for Vision Nasdaq: BLTE an Oral Treatment for Macular Degeneration | | | Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or so ...

Belite Bio, Inc. (NASDAQ:BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim – Cantor Yi Chen - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Hello, and thank you for joining us to discuss Belite Bio's Third Quarter 2024 F ...

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2024. Webcast InformationDate: Tuesd ...

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, a ...

Scholl , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, IncBLTE"Belite Bio""" Hendrik P. N. Scholl Scholl AMD Belite Bio Tinlarebant Belite BioTom Lin"Hendrik Scholl Belite BioScholl 2 3 Belite Bio Tinlarebant TinlarebantHendrik Scholl" " Belite Bio"Scholl "Belite Bio, " Scholl IOB EVICR.net Swiss Association for Research in Vision and Ophthalmology, ARVO-SWISS Scholl · Wilmer · Wilmer · Hendrik SchollProgStar StudyProgStar Study 365 10 280W. Richard GreenPaul HenkindAlfred-Vogt ARVOKupfer 25 Scholl Pro Re ...

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of direc ...

| --- | --- | --- | |-------|--------------------------------------------------------------------------------------|-----------------------------------------------| | | | | | | Q2 2024 Financial Results Conference Call August 12, 2024, 4:30 p.m. ET Nasdaq: BLTE | | | | | For more info please visit: www.belitebio.com | Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, r ...

Belite Bio, Inc (NASDAQ:BLTE) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Yi Chen - H.C. Wainwright Bruce Jackson - Benchmark Operator Hello, and thank you for joining us to discuss Belite Bio's Second Quarter 2024 Financial Results. Joining the call today are Dr. ...

Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase 1b & 2/3 ("DRAGON II") trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six subjects in Japan Tinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1 Pivotal global Phase 3 ...

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. A webcast of the presentation will be available on Thursday, August 15, 2 ...